SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Jun 12, 2019
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: June 12, 2019 · CIK: 0001604191 · Accession: 0000000000-19-009758
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231954
Letter
June 12, 2019 Johan M. (Thijs) Spoor Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY 11226 Re:AzurRx BioPharma, Inc. Registration Statement on Form S-3 Filed June 5, 2019 File No. 333-231954 Dear Mr. Spoor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Jessica R. Sudweeks, Esq.
Show Raw Text
June 12, 2019
Johan M. (Thijs) Spoor
Chief Executive Officer
AzurRx BioPharma, Inc.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, NY 11226
Re:AzurRx BioPharma, Inc.
Registration Statement on Form S-3
Filed June 5, 2019
File No. 333-231954
Dear Mr. Spoor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jessica R. Sudweeks, Esq.